Baxter Research v. Kol Bio-Medical
Opinion
UNPUBLISHED
UNITED STATES COURT OF APPEALS
FOR THE FOURTH CIRCUIT
BAXTER RESEARCH MEDICAL, INCORPORATED, Plaintiff-Appellant,
v.
MEDTRONIC, INCORPORATED, Defendant-Appellee,
and
KOL BIO-MEDICAL INSTRUMENTS, INCORPORATED; ROGER S. KOLASINSKI;
No. 98-1608
TIMOTHY D.C. MCINERNEY; MICHAEL C. WHITAKER, Defendants,
TIM HOLLY; TONY ANTONACCIO; ROBERT CURRAN; DONNA EARLEY; GLENN CONSOR; KATHY KEARNS; STEVE ARCHIBALD; JAKE HOLTZINGER; R. J. KUZNITZ; BRIAN DOORLEY; BRUCE ANGESKI, Intervenors-Defendants.
Appeal from the United States District Court for the Eastern District of Virginia, at Alexandria. Albert V. Bryan, Jr., Senior District Judge. (CA-97-1117-A)
Argued: January 27, 1999
Decided: February 24, 1999
Before WILKINSON, Chief Judge, and NIEMEYER and TRAXLER, Circuit Judges.
Affirmed by unpublished per curiam opinion.
COUNSEL
ARGUED: Warren Eugene Zirkle, MCGUIRE, WOODS, BATTLE & BOOTHE, L.L.P., Richmond, Virginia, for Appellant. Bernard Joseph DiMuro, DIMURO, GINSBERG & LIEBERMAN, Alexandria , Virginia, for Appellee. ON BRIEF: Darryl S. Lew, Robert M. Tyler, MCGUIRE, WOODS, BATTLE & BOOTHE, L.L.P., Richmond , Virginia, for Appellant. Michael E. Barnsback, Elizabeth H. Cronise, DIMURO, GINSBERG & LIEBERMAN, Alexandria, Virginia ; David C. Forsberg, J. Patrick McDavitt, Kathleen Erickson DiGiorno, BRIGGS & MORGAN, Saint Paul, Minnesota, for Appellee .
Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).
OPINION
PER CURIAM:
Baxter Research Medical, Inc. appeals the grant of summary judgment in favor of appellee Medtronic, Inc. on Baxter's tortious interference with contract claim. Baxter argues that Medtronic tortiously interfered by hiring away the sales force of one of Baxter's distributors . Because Virginia law requires a contract breach to support a tortious interference with contract claim, and we find no breach, we affirm the judgment of the district court.
I.
In 1993 KOL Bio-Medical Instruments, Inc. signed an exclusive distributorship agreement with Research Medical, Inc. (RMI) under which KOL was to sell RMI's cardiovascular surgical supplies in
much of the East and Southeast. The agreement provided that KOL was to render its "best efforts" to "promote, market and advertise" RMI's products, and that it was not to compete with RMI by manufacturing competing products or selling the goods of a manufacturer that did. The contract allowed either party to terminate the relationship without cause. If KOL desired to terminate, the agreement required that it provide RMI with six months notice, a period during which KOL's best efforts obligation continued. KOL's covenant not to compete extended twelve months past the notice of termination date.
For a few years, the relationship proceeded well. In late 1996, however , Baxter International, a large manufacturer of surgical supplies, announced that it was purchasing RMI. KOL became concerned that it would lose its distributorship because Baxter had a history of using a direct sales force to sell its products. At the same time, the change to managed care began to erode the profits KOL generated from its sales of cardiovascular products. KOL thus made the decision to exit the cardiovascular products market.
In early 1997 KOL approached Medtronic, another medical device manufacturer, to gauge its interest in acquiring KOL. Medtronic proposed instead that it pay KOL to assist Medtronic in acquiring KOL's cardiovascular sales force. The parties signed a contract wherein Medtronic agreed to pay KOL $6 million for the right to employ KOL's cardiovascular sales team, $4.5 million of which hinged on the final number of salesmen who would ultimately join Medtronic. For its part, KOL agreed to release its salesmen from their covenants not to compete with KOL, sign its own covenant not to compete with Medtronic to begin after its six-month termination period with Baxter ended, and to "use all reasonable efforts to encourage each KOL Sales Representative to accept employment with Medtronic." The agreement also provided that KOL would "fully perform" its obligations under its distributorship agreement with Baxter.
On June 23, 1997, KOL gave its notice of termination to Baxter. Shortly thereafter, KOL informed its sales representatives that, if they joined Medtronic, KOL would release them from their covenants not to compete and pay each a sizable severance bonus. Each of KOL's eleven cardiovascular salesmen joined Medtronic. In their place KOL
substituted three of its principals and its critical care sales force -- a group selling a separate product line. During the termination period KOL's sales of RMI products totaled $3.5 million, an 11.9% increase over the same six-month period of the previous year.
Baxter brought suit in the Federal District Court for the Eastern District of Virginia alleging, inter alia, that Medtronic tortiously interfered with Baxter's distributorship agreement with KOL. The district court, after finding that KOL did not breach the agreement, granted summary judgment to KOL. Baxter appeals, and we affirm.
II.
Baxter claims that Medtronic tortiously interfered with its distributorship agreement with KOL. Under Virginia law, one must demonstrate a contract breach to support a tortious interference claim. Chaves v. Johnson, 335 S.E.2d 97, 102 (Va. 1985). We hold that Baxter cannot demonstrate such a breach.
A.
Initially, Baxter alleges that KOL breached the contract's best efforts clause. Paragraph 3.A of the contract provided that "[t]he Distributor shall use its best efforts to promote, market and advertise the sale of the Products in the Territory." When KOL released its cardiovascular team, it replaced it with its three principals who were fully trained in and who possessed extensive knowledge of the cardiovascular products market. In addition, KOL used its critical care sales force which already sold similar products to the same accounts. Together, this sales force generated $3.5 million in sales, an 11.9% increase over the same six-month period of the previous year and more than KOL had ever sold in any six-month period in its entire history with RMI. Nevertheless, Baxter contends that KOL failed to provide its best efforts because it released its cardiovascular sales force and replaced it with an inferior team.
Baxter's reading of the contract contradicts its plain language. The best efforts clause pertains to nothing more than efforts to "promote, market and advertise" Baxter's products. It says nothing about per-
sonnel. Indeed, its silence should come as no surprise since another provision of the contract, Paragraph 3.B, deals specifically with personnel . Paragraph 3.B provides that "[t]he Distributor shall employ competent and professional sales personnel." Interpreting the best efforts clause to contain a personnel component would render the personnel clause superfluous. And reading the two clauses together, as we must, leads to the conclusion that the best efforts clause means nothing more than KOL is to provide its best efforts with the people it has. The personnel clause dictates their qualifications.1
Baxter, however, seeks to convert the best efforts clause into a repository for unbargained-for contract conditions. Baxter maintains that the best efforts clause barred KOL's efforts to help its sales representatives find jobs after KOL decided to exit the business. No reading of the words "best efforts to promote, market and advertise" could support such a restriction. If Baxter desired a contract with these terms, it was free to negotiate for them. This court, however, is not free to rewrite the bargain of the parties.
Free access — add to your briefcase to read the full text and ask questions with AI
Baxter Research v. Kol Bio-Medical (Baxter Research v. Kol Bio-Medical) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.